Alnylam Pharmaceuticals Inc (ALNY)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Yvonne L. Greenstreet
Employees:
1,660
300 THIRD STREET, CAMBRIDGE, MA 02142
(617) 551-8200

Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Data derived from most recent annual or quarterly report
Market Cap 28.711 Billion Shares Outstanding123.028 Million Avg 30-day Volume 757.488 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.32
Price to Revenue25.4473 Debt to Equity-15.0208 EBITDA-860.842 Million
Price to Book Value0.0 Operating Margin-82.3191 Enterprise Value23.154 Billion
Current Ratio3.482 EPS Growth-0.368 Quick Ratio3.17
1 Yr BETA 1.0176 52-week High/Low 242.97 / 117.58 Profit Margin-123.0202
Operating Cash Flow Growth8.9896 Altman Z-Score1.5955 Free Cash Flow to Firm -366.395 Million
Earnings Report2023-02-23
View SEC Filings from ALNY instead.

View recent insider trading info

Alnylam Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ALNY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALNY

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-03 by FRANCHINI INDRANI LALL
  • 4: filed on 2023-02-03 by TANGULER TOLGA
  • 4: filed on 2023-01-09 by BERTOZZI CAROLYN R
  • 3: filed on 2023-01-09 by BERTOZZI CAROLYN R
  • 4: filed on 2022-12-07 by VAISHNAW AKSHAY
  • 4: filed on 2022-11-23 by AUSIELLO DENNIS A
  • 4: filed on 2022-08-24 by SIGAL CHARLES ELLIOTT
  • 3: filed on 2022-08-24 by SIGAL CHARLES ELLIOTT
  • 4: filed on 2022-08-17 by SHARP PHILIP A
  • 4: filed on 2022-08-05 by TANGULER TOLGA

    • Events (8k)

  • 8-K: filed on 2023-01-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-24:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-07-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-23:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    6.7 Thousand total shares from 13 transactions

    Exercise Derivative Conversion (M)

    10.2 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FRANCHINI INDRANI LALL EVP, CLO & SECRETARY

    • Officer
    		 3,500 2023-02-01 1

    TANGULER TOLGA EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-02-01 4

    BERTOZZI CAROLYN R

    • Director
    		 4,268 2023-01-05 2

    VAISHNAW AKSHAY PRESIDENT

    • Officer
    		 82,405 2022-12-05 3

    AUSIELLO DENNIS A

    • Director
    		 3,500 2022-11-21 3

    SIGAL CHARLES ELLIOTT

    • Director
    		 4,456 2022-08-22 2

    SHARP PHILLIP A

    • Director
    		 266,899 2022-08-15 3

    GREENSTREET YVONNE CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 48,399 2022-08-03 2

    POULTON JEFFREY V. EVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 23,923 2022-08-03 2

    GARG PUSHKAL CMO & EVP DEV & MED AFFAIRS

    • Officer
    		 18,098 2022-08-03 2

    PYOTT DAVID E I

    • Director
    		 5,153 2022-05-18 2

    HAMBURG MARGARET A

    • Director
    		 5,153 2022-05-18 2

    FANUCCI MARSHA

    • Director
    		 5,153 2022-05-18 2

    SCHULMAN AMY W

    • Director
    		 5,153 2022-05-18 2

    BRANDICOURT OLIVIER

    • Director
    		 5,153 2022-05-18 1

    REITAN COLLEEN F

    • Director
    		 5,153 2022-05-18 1

    PAUL STEVEN M

    • Director
    		 1,000 2022-04-01 1

    MARAGANORE JOHN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 465,095 2021-12-21 0

    KEATING LAURIE EVP, CHIEF LEGAL OFFICER

    • Officer
    		 6,690 2021-08-05 0

    BONNEY MICHAEL W EXECUTIVE CHAIR

    • Officer
    • Director
    		 22,477 2021-08-02 0

    GREENE BARRY E PRESIDENT

    • Officer
    		 73,501 2020-09-09 0

    SCHIMMEL PAUL

    • Director
    		 0 2019-07-01 0

    SONI MANMEET SINGH CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2019-02-28 0

    SANOFI

    • 10% Owner
    		 No longer subject to file 2019-01-17 0

    MASON MICHAEL VP, FINANCE AND TREASURER

    • Officer
    		 0 2018-09-27 0

    CLARKE JOHN K

    • Director
    		 0 2018-06-20 0

    STARR KEVIN P

    • Director
    		 0 2017-06-02 0

    GROS DAVID-ALEXANDRE C SVP, CHIEF BUSINESS OFFICER

    • Officer
    		 0 2016-12-20 0

    REID LAURENCE SVP, CHIEF BUSINESS OFFICER

    • Officer
    		 No longer subject to file 2014-12-31 0

    DZAU VICTOR J

    • Director
    		 0 2013-06-06 0

    NOVARTIS AG

    NOVARTIS PHARMA AG

    • 10% Owner
    		 No longer subject to file 2012-09-20 0

    ALLEN PATRICIA L VP OF FINANCE AND TREASURER

    • Officer
    		 1,165 2010-12-08 0

    KOBLAN KENNETH S CHIEF SCIENTIFIC OFFICER

    • Officer
    		 357 2010-12-08 0

    VINCENT JAMES L

    • Director
    		 0 2010-06-17 0

    SATO VICKI L

    • Director
    		 0 2010-06-02 0

    SCOLNICK EDWARD M

    • Director
    		 0 2009-06-11 0

    SCHMIDT JOHN A JR SVP, CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2008-12-09 0

    BARRETT PETER

    • Director
    		 10,000 2006-06-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-03 S 128 $227.68 d 3,296 direct yes

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-03 S 185 $230.20 d 3,111 direct yes

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-03 S 865 $231.35 d 2,246 direct yes

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-03 S 1,293 $232.53 d 953 direct yes

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-03 S 953 $233.31 d 0 direct yes

    FRANCHINI INDRANI LALL - Officer EVP, CLO & SECRETARY

    		2023-02-03 17:46:11 -0500 2023-02-02 S 5 $227.38 d 3,500 direct

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-02 S 73 $223.97 d 4,952 direct

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-02 S 963 $225.80 d 3,989 direct

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-02 S 561 $226.62 d 3,428 direct

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-02 S 4 $227.38 d 3,424 direct

    FRANCHINI INDRANI LALL - Officer EVP, CLO & SECRETARY

    		2023-02-03 17:46:11 -0500 2023-02-02 S 586 $226.62 d 3,505 direct

    FRANCHINI INDRANI LALL - Officer EVP, CLO & SECRETARY

    		2023-02-03 17:46:11 -0500 2023-02-02 S 1,007 $225.80 d 4,091 direct

    FRANCHINI INDRANI LALL - Officer EVP, CLO & SECRETARY

    		2023-02-03 17:46:11 -0500 2023-02-02 S 77 $223.97 d 5,098 direct

    FRANCHINI INDRANI LALL - Officer EVP, CLO & SECRETARY

    		2023-02-03 17:46:11 -0500 2023-02-01 M 5,175 d 10,350 direct

    FRANCHINI INDRANI LALL - Officer EVP, CLO & SECRETARY

    		2023-02-03 17:46:11 -0500 2023-02-01 M 5,175 a 5,175 direct

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-01 M 5,025 d 0 direct

    TANGULER TOLGA - Officer EVP, CHIEF COMMERCIAL OFFICER

    		2023-02-03 17:45:42 -0500 2023-02-01 M 5,025 a 5,025 direct

    BERTOZZI CAROLYN R - Director

    		2023-01-09 16:06:45 -0500 2023-01-05 A 4,268 a 4,268 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 22:15:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 21:45:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 21:15:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 20:45:06 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 20:15:04 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 19:45:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 19:15:04 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 18:45:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 18:15:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 17:45:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 17:15:04 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 16:45:04 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 16:15:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 15:45:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 15:15:03 UTC 4.32 0.25 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 14:45:04 UTC 4.0566 0.2634 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 14:15:04 UTC 4.0566 0.2634 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 13:45:03 UTC 4.0566 0.2634 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 13:15:03 UTC 4.0566 0.2634 1600000
    ALNYLAM PHARMACEUTICALS INC ALNY 2023-02-03 12:45:03 UTC 4.0566 0.2634 1600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund ALNY -25.0 shares, $-3640.0 2020-09-30 N-PORT
    AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund ALNY -598.0 shares, $-48091.16 2019-09-30 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund ALNY -8.0 shares, $-1164.8 2020-09-30 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund ALNY -1153.0 shares, $-162792.07 2021-03-31 N-PORT
    JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund ALNY -4805.0 shares, $-678417.95 2021-03-31 N-PORT
    SCHWAB CAPITAL TRUST- Schwab Hedged Equity Fund ALNY -351.0 shares, $-62807.94 2021-07-31 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Strategic Equity Fund ALNY -1901.0 shares, $-380504.16 2022-09-30 N-PORT
    Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund ALNY -829.0 shares, $-165932.64 2022-09-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund ALNY -540.0 shares, $-108086.4 2022-09-30 N-PORT
    AQR Funds- AQR Alternative Risk Premia Fund ALNY -885.0 shares, $-177141.6 2022-09-30 N-PORT
    FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND ALNY -2400.0 shares, $-480384.0 2022-09-30 N-PORT
    RUSSELL INVESTMENT CO- Sustainable Equity Fund ALNY -964.0 shares, $-199798.64 2022-10-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Strategic Equity Fund ALNY -12407.0 shares, $-2571474.82 2022-10-31 N-PORT
    Calamos Investment Trust/IL- Calamos Market Neutral Income Fund ALNY -38300.0 shares, $-7938058.0 2022-10-31 N-PORT
    Steward Funds Inc- Steward Equity Market Neutral Fund ALNY -1700.0 shares, $-352342.0 2022-10-31 N-PORT
    Principal Funds, Inc- Global Multi-Strategy Fund ALNY 150.0 shares, $-33088.5 2022-11-30 N-PORT
    GMO TRUST- GMO Alternative Allocation Fund ALNY -1800.0 shares, $-397062.0 2022-11-30 N-PORT
    GMO TRUST- GMO Strategic Opportunities Allocation Fund ALNY -1200.0 shares, $-264708.0 2022-11-30 N-PORT
    GMO TRUST- GMO Implementation Fund ALNY -31900.0 shares, $-7036821.0 2022-11-30 N-PORT
    GMO TRUST- GMO Benchmark-Free Fund ALNY -9400.0 shares, $-2073546.0 2022-11-30 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Josh Gottheimer democrat House Filing 2022-10-05 2022-09-28 JT P $1,001-$15,000

    Elevate your investments